Portfolio News

On December 4, 2024, Everest Medicines (HKEX 1952.HK), a partner of Suzhou Evopoint Biosciences Co., Ltd. (referred to as "Evopoint" or "the company"), reported positive interim results of a phase 1b/2a clinical trial for EVER001 capsule (XNW1011), a globally licensed pipeline product, in the treatment of primary membranous nephropathy (pMN). In September 2021, Evopoint granted global development, manufacturing, and commercialization rights for their novel covalent reversible BTK inhibitor XNW1011 in the field of renal diseases to Everest Medicines.

 

Everest Medicines announces positive interim results from phase 1b/2a clinical trial of the novel BTK inhibitor EVER001 for primary membranous nephropathy.

 

Dr. Qiang Jing, Chairman of Evopoint, remarked, "XNW1011 is a covalent, reversible Bruton's tyrosine kinase (BTK) inhibitor that has demonstrated exceptional  performance in clinical studies. The recent positive interim results shared by Everest Medicines underscore  the immense potential of XNW1011 and mark a significant milestone in the collaborative licensing  agreement between Evopoint and Everest Medicines."

 

Leveraging itsstrong R&D capabilities and a rich pipeline of innovative drugs, Evopoint continues to drive progress and development in the global pharmaceutical industry. This successful collaboration with Everest Medicines will further enhance Evopoint’s global market reach and deepen its influence within the industry.